HF 289 (see companion bill SF 366) – Minnesota

Status: Inactive / Dead
Year Introduced: 2019
Link: https://www.revisor.mn.gov/bills/bill.php?b=House&f=HF0289&ssn=0&y=2019

Diabetes prescription drugs cost reporting required. This bill requires the commissioner of health to compile reports of essential prescription drugs used to treat diabetes and on the wholesale acquisition costs for these drugs that have increased above certain amounts in the preceding one-year or two-year periods, and to submit an annual report to the legislature on price increases for essential diabetes drugs. It also requires drug manufacturers to report information on the costs of these drugs and factors that led to increases in their wholesale acquisition costs. Further, it requires pharmacy benefit managers to report information on rebates related to essential diabetes drugs; health plan companies to report information on premiums,
spending on essential diabetes drugs, and the use of pharmacy benefit managers; and pharmacies to report information on payments made and received for essential diabetes drugs.

Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found